Jilin Province Huinan Changlong Bio-pharmacy Past Earnings Performance
Past criteria checks 2/6
Jilin Province Huinan Changlong Bio-pharmacy has been growing earnings at an average annual rate of 5.7%, while the Pharmaceuticals industry saw earnings growing at 5.7% annually. Revenues have been growing at an average rate of 8.1% per year. Jilin Province Huinan Changlong Bio-pharmacy's return on equity is 10.8%, and it has net margins of 20.5%.
Key information
5.7%
Earnings growth rate
5.7%
EPS growth rate
| Pharmaceuticals Industry Growth | 5.6% |
| Revenue growth rate | 8.1% |
| Return on equity | 10.8% |
| Net Margin | 20.5% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Here's Why Shareholders May Consider Paying Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) CEO A Little More
May 21
There May Be Reason For Hope In Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) Disappointing Earnings
Apr 04With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case
Mar 26Investors Don't See Light At End Of Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Tunnel
Dec 27With EPS Growth And More, Jilin Province Huinan Changlong Bio-pharmacy (HKG:8049) Makes An Interesting Case
Jul 12It's Unlikely That Shareholders Will Increase Jilin Province Huinan Changlong Bio-pharmacy Company Limited's (HKG:8049) Compensation By Much This Year
Jun 05How Is Jilin Province Huinan Changlong Bio-pharmacy's (HKG:8049) CEO Paid Relative To Peers?
Nov 26Revenue & Expenses Breakdown
How Jilin Province Huinan Changlong Bio-pharmacy makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 839 | 172 | 492 | 0 |
| 31 Mar 24 | 896 | 148 | 478 | 0 |
| 31 Dec 23 | 842 | 148 | 449 | 0 |
| 30 Sep 23 | 841 | 222 | 434 | 0 |
| 30 Jun 23 | 860 | 197 | 466 | 0 |
| 31 Mar 23 | 791 | 212 | 462 | 0 |
| 31 Dec 22 | 842 | 194 | 510 | 0 |
| 30 Sep 22 | 825 | 151 | 543 | 0 |
| 30 Jun 22 | 781 | 172 | 487 | 0 |
| 31 Mar 22 | 750 | 157 | 473 | 0 |
| 31 Dec 21 | 705 | 143 | 453 | 0 |
| 30 Sep 21 | 655 | 141 | 400 | 0 |
| 30 Jun 21 | 638 | 124 | 409 | 0 |
| 31 Mar 21 | 641 | 133 | 425 | 0 |
| 31 Dec 20 | 622 | 127 | 428 | 0 |
| 30 Sep 20 | 614 | 140 | 385 | 0 |
| 30 Jun 20 | 632 | 143 | 397 | 0 |
| 31 Mar 20 | 635 | 143 | 405 | 0 |
| 31 Dec 19 | 646 | 145 | 401 | 0 |
| 30 Sep 19 | 637 | 157 | 410 | 0 |
| 30 Jun 19 | 635 | 159 | 403 | 0 |
| 31 Mar 19 | 628 | 158 | 396 | 0 |
| 31 Dec 18 | 648 | 161 | 404 | 0 |
| 30 Sep 18 | 646 | 144 | 392 | 0 |
| 30 Jun 18 | 648 | 144 | 392 | 0 |
| 31 Mar 18 | 653 | 145 | 388 | 0 |
| 31 Dec 17 | 645 | 144 | 382 | 0 |
| 30 Sep 17 | 663 | 146 | 391 | 0 |
| 30 Jun 17 | 667 | 145 | 384 | 0 |
| 31 Mar 17 | 658 | 144 | 373 | 0 |
| 31 Dec 16 | 654 | 143 | 368 | 0 |
| 30 Sep 16 | 614 | 125 | 348 | 0 |
| 30 Jun 16 | 572 | 116 | 335 | 0 |
| 31 Mar 16 | 567 | 120 | 336 | 0 |
| 31 Dec 15 | 539 | 118 | 317 | 0 |
| 30 Sep 15 | 623 | 138 | 373 | 0 |
| 30 Jun 15 | 624 | 138 | 368 | 0 |
| 31 Mar 15 | 616 | 135 | 355 | 0 |
| 31 Dec 14 | 602 | 133 | 345 | 0 |
| 30 Sep 14 | 518 | 91 | 314 | 0 |
| 30 Jun 14 | 487 | 85 | 299 | 0 |
| 31 Mar 14 | 466 | 81 | 292 | 0 |
| 31 Dec 13 | 458 | 79 | 293 | 0 |
Quality Earnings: 8049 has high quality earnings.
Growing Profit Margin: 8049's current net profit margins (20.5%) are lower than last year (22.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 8049's earnings have grown by 5.7% per year over the past 5 years.
Accelerating Growth: 8049's has had negative earnings growth over the past year, so it can't be compared to its 5-year average.
Earnings vs Industry: 8049 had negative earnings growth (-12.9%) over the past year, making it difficult to compare to the Pharmaceuticals industry average (6.4%).
Return on Equity
High ROE: 8049's Return on Equity (10.8%) is considered low.